• An application to Health Canada (HC) to market a new drug in Canada is done by the sponsoring pharmaceutical company; the application typically includes animal data, chemistry and manufacturing data, and the results from clinical trials of various phases. The amount of data submitted in support of a new chemical entity frequently reaches hundreds of volumes.• The role of drug evaluators is to critically assess both the data and the sponsor's interpretation of the data in order to determine, on a population basis, the potential benefits and the potential harms (i.e., risks) associated with taking the drug. Evaluators apply regulatory expertise to reach an evidence-and contextbased recommendation as to the risk-benefit profile of the drug within the context of the proposed conditions of use. ABSTRACT:The role of regulatory drug submission evaluators in Canada is to critically assess both the data submitted and the sponsor's interpretation of the data in order to reach an evidence-, and context-based recommendation as to the potential benefits and potential harms (i.e., risks) associated with taking the drug under the proposed conditions of use. The purpose of this document is to outline the regulatory framework in which this assessment occurs, including: defining what "authorization to market a drug in Canada" means, in terms of the role of the sponsor, the responsibility of Health Canada in applying the Food and Drugs Act prior to and after marketing authorization, and the distinction between regulatory authorization versus physician authorization; highlighting organizational, process and legal factors within Health Canada related to authorization of clinical trials and authorization to market a drug; considerations during the review process, such as regulatory and scientific issues related to the drug, patient populations and trial designs; application of international guidelines, and decisions from other jurisdictions; regulatory realities regarding drug authorization, including the requirement for wording in the Product Monograph to accurately reflect the information currently available on the safe and effective use of a drug, and that hypothesis-confirming studies are essential to regulatory endorsement; current issues related to the review of therapies for dementia, such as assessing preventative treatments, and therapies that have symptomatic versus disease-modifying effects, statistical issues regarding missing data, and trial design issues. RÉSUMÉ: Cadre de réglementation canadien sur les médicaments. Au Canada, le rôle de ceux qui évaluent les soumissions à l'organisme de réglementation est critique, tant en ce qui concerne l'évaluation des données soumises que leur interprétation par le promoteur afin d'arriver à une recommandation basée sur les données et sur le contexte quant aux bénéfices et aux dangers (c.-à-d. aux risques) potentiels associés à la prise du médicament, tels que décrits dans la soumission. Le but de ce document est de faire une esquisse du cadre réglementaire régissant cette évalua...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.